Amarin Corp Plcuk (AMRN) EPS (Basic) Growth (3y) (2013 - 2026)
Amarin Corp Plcuk (AMRN) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -34.06% |
| 10 | Amarin Corp Plcuk | 5.88 Bn | 5.56 Bn | 14.99 Mn | 24.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -104.35% |
| Mar 31, 2026 | -131.34% |
| Dec 31, 2025 | -209.49% |
| Sep 30, 2025 | -208.35% |
| Jun 30, 2025 | -57.18% |
| Mar 31, 2025 | -112.32% |
| Dec 31, 2024 | -73.11% |
| Sep 30, 2024 | -22.62% |
| Jun 30, 2024 | -42.73% |
| Mar 31, 2024 | -390.20% |
| Dec 31, 2023 | -45.79% |
| Sep 30, 2023 | -39.50% |
| Jun 30, 2023 | -79.17% |
| Mar 31, 2023 | 10.70% |
| Dec 31, 2022 | -53.06% |
| Sep 30, 2022 | -8.80% |
| Jun 30, 2022 | -217.28% |
| Mar 31, 2022 | -2.20% |
| Dec 31, 2021 | 32.53% |
| Sep 30, 2021 | 26.29% |